These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
152 related articles for article (PubMed ID: 33598568)
1. Bedaquiline for multidrug-resistant tuberculosis and QTc prolongation in California. Katrak S; Lowenthal P; Shen R; True L; Henry L; Barry P J Clin Tuberc Other Mycobact Dis; 2021 May; 23():100216. PubMed ID: 33598568 [TBL] [Abstract][Full Text] [Related]
2. Identification of urine biomarkers predictive of prolonged QTc interval in multidrug-resistant tuberculosis patients treated with bedaquiline. Yu J; Ren W; Yuan J; Liu R; Ma L; Tang S; Pang Y Front Pharmacol; 2024; 15():1362544. PubMed ID: 38873419 [TBL] [Abstract][Full Text] [Related]
3. Analysis of the side effect of QTc interval prolongation in the bedaquiline regimen in drug resistant tuberculosis patients. Ardhianto D; Suharjono ; Soedarsono ; Fatmawati U J Basic Clin Physiol Pharmacol; 2021 Jun; 32(4):421-427. PubMed ID: 34214323 [TBL] [Abstract][Full Text] [Related]
4. Development and Validation of a Nomogram for Prediction of QT Interval Prolongation in Patients Administered Bedaquiline-Containing Regimens in China: a Modeling Study. Liu F; Gao J; Gao M; Liu Y; Shu W; Xie L; Sun Y; Zhang L; Li L; Pang Y Antimicrob Agents Chemother; 2022 Sep; 66(9):e0203321. PubMed ID: 36047781 [TBL] [Abstract][Full Text] [Related]
5. Early treatment outcome of bedaquiline plus optimised background regimen in drug resistant tuberculosis patients. Barvaliya SV; Desai MK; Panchal JR; Solanki RN Indian J Tuberc; 2020 Apr; 67(2):222-230. PubMed ID: 32553316 [TBL] [Abstract][Full Text] [Related]
6. Bedaquiline in the treatment of multidrug- and extensively drug-resistant tuberculosis in China. Han X; Chen X; Sha W; Zhang X; Qiu L; Wang J; Wu G; Yao L; Lv Y; Zhang X; Zhou J; Tang S; Chu N Int J Tuberc Lung Dis; 2020 Aug; 24(8):789-794. PubMed ID: 32912383 [No Abstract] [Full Text] [Related]
7. One Step Forward: Successful End-of-Treatment Outcomes of Patients With Drug-Resistant Tuberculosis Who Received Concomitant Bedaquiline and Delamanid in Mumbai, India. Das M; Dalal A; Laxmeshwar C; Ravi S; Mamnoon F; Meneguim AC; Paryani R; Mathur T; Singh P; Mansoor H; Kalon S; Hossain FN; Lachenal N; Coutisson S; Ferlazzo G; Isaakidis P Clin Infect Dis; 2021 Nov; 73(9):e3496-e3504. PubMed ID: 33079176 [TBL] [Abstract][Full Text] [Related]
8. Bedaquiline Effect on QT Interval of Drugs-Resistant Tuberculosis Patients: Real World Data. Darmayani IGAAPS; Ascobat P; Instiaty I; Sugiri YJR; Sawitri N Acta Med Indones; 2022 Jul; 54(3):389-396. PubMed ID: 36156479 [TBL] [Abstract][Full Text] [Related]
9. Effectiveness and safety of bedaquiline under conditional access program for treatment of drug-resistant tuberculosis in India: An interim analysis. Salhotra VS; Sachdeva KS; Kshirsagar N; Parmar M; Ramachandran R; Padmapriyadarsini C; Patel Y; Mehandru L; Jaju J; Ponnuraja C; Gupta M; Kalaiselvan V; Shamim A; Khaparde S; Swaminathan S; Indian J Tuberc; 2020 Jan; 67(1):29-37. PubMed ID: 32192613 [TBL] [Abstract][Full Text] [Related]
10. Exposure-safety analysis of QTc interval and transaminase levels following bedaquiline administration in patients with drug-resistant tuberculosis. Tanneau L; Svensson EM; Rossenu S; Karlsson MO CPT Pharmacometrics Syst Pharmacol; 2021 Dec; 10(12):1538-1549. PubMed ID: 34626526 [TBL] [Abstract][Full Text] [Related]
11. Safety and effectiveness of all-oral and injectable-containing, bedaquiline-based long treatment regimen for pre-XDR tuberculosis in Vietnam. Nguyen TMP; Nguyen BH; Hoang TTT; Nguyen HA; Vu DH; Nguyen MH; Nguyen BN; Decroo T; Nguyen VN Front Pharmacol; 2022; 13():1023704. PubMed ID: 36313324 [No Abstract] [Full Text] [Related]
12. Successful implementation of bedaquiline for multidrug-resistant TB treatment in remote Papua New Guinea. Taune M; Ustero P; Hiashiri S; Huang K; Aia P; Morris L; Main S; Chan G; du Cros P; Majumdar SS Public Health Action; 2019 Sep; 9(Suppl 1):S73-S79. PubMed ID: 31579654 [TBL] [Abstract][Full Text] [Related]
13. Safety, efficacy, and serum concentration monitoring of bedaquiline in Chinese patients with multidrug-resistant tuberculosis. Li J; Yang G; Cai Q; Wang Y; Xu Y; Zhang R; Lang Y; Cai X Int J Infect Dis; 2021 Sep; 110():179-186. PubMed ID: 34293490 [TBL] [Abstract][Full Text] [Related]
14. Reduced Susceptibility of Mycobacterium tuberculosis to Bedaquiline During Antituberculosis Treatment and Its Correlation With Clinical Outcomes in China. Liu Y; Gao M; Du J; Wang L; Gao J; Shu W; Wang Y; Xue Z; Li L; Pang Y Clin Infect Dis; 2021 Nov; 73(9):e3391-e3397. PubMed ID: 32667984 [TBL] [Abstract][Full Text] [Related]
15. Emergence of nontuberculous mycobacteria infections during bedaquiline-containing regimens in multidrug-resistant tuberculosis patients. Gao J; Pei Y; Yan X; Shi G; Li T; Gao M; Liu Y; Wang Y; Shu W; Li L; Pang Y Int J Infect Dis; 2020 Nov; 100():196-198. PubMed ID: 32890726 [TBL] [Abstract][Full Text] [Related]
16. Interim Effectiveness and Safety Comparison of Bedaquiline-Containing Regimens for Treatment of Diabetic Versus Non-Diabetic MDR/XDR-TB Patients in China: A Multicenter Retrospective Cohort Study. Shi L; Gao J; Gao M; Deng P; Chen S; He M; Feng W; Yang X; Huang Y; He F; Hu Y; Lei L; Li X; Du J; Hu X; Liu Z; Tang P; Han J; Wang H; Han Y; Shu W; Sun Y; Pei Y; Liu Y Infect Dis Ther; 2021 Mar; 10(1):457-470. PubMed ID: 33515206 [TBL] [Abstract][Full Text] [Related]
17. Acquisition of clofazimine resistance following bedaquiline treatment for multidrug-resistant tuberculosis. Liu Y; Gao J; Du J; Shu W; Wang L; Wang Y; Xue Z; Li L; Xu S; Pang Y Int J Infect Dis; 2021 Jan; 102():392-396. PubMed ID: 33130209 [TBL] [Abstract][Full Text] [Related]
18. Bedaquiline for the Treatment of Multidrug-resistant Tuberculosis in the United States. Mase S; Chorba T; Parks S; Belanger A; Dworkin F; Seaworth B; Warkentin J; Barry P; Shah N Clin Infect Dis; 2020 Aug; 71(4):1010-1016. PubMed ID: 31556947 [TBL] [Abstract][Full Text] [Related]
19. Early outcome and safety of bedaquiline-containing regimens for treatment of MDR- and XDR-TB in China: a multicentre study. Gao M; Gao J; Xie L; Wu G; Chen W; Chen Y; Pei Y; Li G; Liu Y; Shu W; Fan L; Wu Q; Du J; Chen X; Tang P; Xiong Y; Li M; Cai Q; Jin L; Mei Z; Pang Y; Li L Clin Microbiol Infect; 2021 Apr; 27(4):597-602. PubMed ID: 32553880 [TBL] [Abstract][Full Text] [Related]
20. Long-term plasma pharmacokinetics of bedaquiline for multidrug- and extensively drug-resistant tuberculosis. Perrineau S; Lachâtre M; Lê MP; Rioux C; Loubet P; Fréchet-Jachym M; Gonzales MC; Grall N; Bouvet E; Veziris N; Yazdanpanah Y; Peytavin G Int J Tuberc Lung Dis; 2019 Jan; 23(1):99-104. PubMed ID: 30674381 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]